Working… Menu

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02211014
Recruitment Status : Completed
First Posted : August 7, 2014
Last Update Posted : June 19, 2019
Acerta Pharma, LLC
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 26, 2019
Actual Study Completion Date : April 26, 2019